ZA200705083B - Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders - Google Patents
Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disordersInfo
- Publication number
- ZA200705083B ZA200705083B ZA200705083A ZA200705083A ZA200705083B ZA 200705083 B ZA200705083 B ZA 200705083B ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 B ZA200705083 B ZA 200705083B
- Authority
- ZA
- South Africa
- Prior art keywords
- agonist
- prevention
- treatment
- neurodegenerative disorders
- neurodegenerative
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63576604P | 2004-12-14 | 2004-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200705083B true ZA200705083B (en) | 2010-03-31 |
Family
ID=36177731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200705083A ZA200705083B (en) | 2004-12-14 | 2007-06-13 | Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060128744A1 (enExample) |
| EP (1) | EP1824464A1 (enExample) |
| JP (1) | JP2008523146A (enExample) |
| KR (1) | KR20070088770A (enExample) |
| CN (1) | CN101098683A (enExample) |
| AU (1) | AU2005316675A1 (enExample) |
| BR (1) | BRPI0519036A2 (enExample) |
| CA (1) | CA2590841A1 (enExample) |
| CR (1) | CR9200A (enExample) |
| IL (1) | IL183859A0 (enExample) |
| MX (1) | MX2007007206A (enExample) |
| NO (1) | NO20073104L (enExample) |
| RU (1) | RU2007122450A (enExample) |
| WO (1) | WO2006065710A1 (enExample) |
| ZA (1) | ZA200705083B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| JP2005305107A (ja) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | 価値的情報値の測定装置およびこれを使用した測定方法 |
| US8604031B2 (en) | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| CN104557664B (zh) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| DK1455779T3 (da) * | 2001-12-20 | 2006-10-30 | Wyeth Corp | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander |
| UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2005
- 2005-12-12 BR BRPI0519036-3A patent/BRPI0519036A2/pt not_active IP Right Cessation
- 2005-12-12 RU RU2007122450/14A patent/RU2007122450A/ru not_active Application Discontinuation
- 2005-12-12 MX MX2007007206A patent/MX2007007206A/es unknown
- 2005-12-12 CN CNA2005800464202A patent/CN101098683A/zh not_active Withdrawn
- 2005-12-12 CA CA002590841A patent/CA2590841A1/en not_active Abandoned
- 2005-12-12 EP EP05853687A patent/EP1824464A1/en not_active Withdrawn
- 2005-12-12 JP JP2007546799A patent/JP2008523146A/ja not_active Withdrawn
- 2005-12-12 WO PCT/US2005/044820 patent/WO2006065710A1/en not_active Ceased
- 2005-12-12 KR KR1020077015556A patent/KR20070088770A/ko not_active Withdrawn
- 2005-12-12 AU AU2005316675A patent/AU2005316675A1/en not_active Abandoned
- 2005-12-13 US US11/301,445 patent/US20060128744A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183859A patent/IL183859A0/en unknown
- 2007-06-13 ZA ZA200705083A patent/ZA200705083B/xx unknown
- 2007-06-18 NO NO20073104A patent/NO20073104L/no not_active Application Discontinuation
- 2007-06-20 CR CR9200A patent/CR9200A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1824464A1 (en) | 2007-08-29 |
| KR20070088770A (ko) | 2007-08-29 |
| JP2008523146A (ja) | 2008-07-03 |
| CA2590841A1 (en) | 2006-06-22 |
| NO20073104L (no) | 2007-07-02 |
| RU2007122450A (ru) | 2009-01-27 |
| WO2006065710A1 (en) | 2006-06-22 |
| CR9200A (es) | 2007-09-07 |
| CN101098683A (zh) | 2008-01-02 |
| MX2007007206A (es) | 2008-03-26 |
| IL183859A0 (en) | 2008-12-29 |
| US20060128744A1 (en) | 2006-06-15 |
| BRPI0519036A2 (pt) | 2008-12-23 |
| AU2005316675A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
| IL230241A (en) | Retinal history and methods of using them to treat visual irregularities | |
| IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
| ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
| IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
| IL182574A0 (en) | Gpr41 and modulators thereof for the treatment of insulin-related disorders | |
| IL180108A0 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
| IL190201A0 (en) | Pde inhibitors and combinations thereof for the treatment of urological disorders | |
| IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| IL187248A0 (en) | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders | |
| IL183859A0 (en) | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders | |
| GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
| IL193799A0 (en) | New therapeutic combinations for the treatment or prevention of psycotic disorders | |
| IL177955A0 (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
| EP1812009A4 (en) | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS | |
| PL1727545T3 (pl) | Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych | |
| HK1102260A (en) | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders | |
| GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
| PL1732558T3 (pl) | Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia bólu | |
| IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain | |
| ZA200802668B (en) | PDE inhibitors and combinations thereof for the treatment of urological disorders | |
| EP1928473A4 (en) | COMBINATION OF POLYCHITOSAMINE AND FIBRATE FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA | |
| ZA200704412B (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| GB0513413D0 (en) | The treatment of inflammatory disorders and pain |